Atea Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $351.4M | $48.6M | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $148.0M | $144.1M | $114.2M | $81.9M | $167.2M | $38.0M | $10.2M |
| SG&A Expense | — | $32.9M | $48.8M | $49.9M | $48.7M | $45.8M | $21.6M | $4.4M |
| Operating Income | — | $-180.9M | $-193.0M | $-164.2M | $-130.7M | $138.4M | $-11.0M | $-14.6M |
| Operating Margin | — | — | — | — | — | 39.4% | -22.7% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-164.5M | $-167.5M | $-134.9M | $-119.5M | $138.6M | $-10.9M | $-14.0M |
| Income Tax Expense | — | $-6.2M | $925.0K | $1.0M | $-3.6M | $17.4M | — | — |
| Net Income | — | $-158.3M | $-168.4M | $-136.0M | $-115.9M | $121.2M | $-10.9M | $-14.0M |
| Net Margin | — | — | — | — | — | 34.5% | -22.5% | — |
| EPS (Basic) | — | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.46 | $-0.13 | $-0.17 |
| EPS (Diluted) | — | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.37 | $-0.13 | $-0.17 |
| Shares Outstanding (Basic) | 79.7M | 81.5M | 84.3M | 83.4M | 83.2M | 82.8M | 86.4M | 80.7M |
| Shares Outstanding (Diluted) | 79.7M | 81.5M | 84.3M | 83.4M | 83.2M | 88.2M | 86.4M | 80.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |